Welcome to our dedicated news page for Oric Pharmaceuticals (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oric Pharmaceuticals 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oric Pharmaceuticals 's position in the market.
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. (ORIC) will participate in two investor conferences in February, including the 6th Annual Guggenheim Biotechnology Conference and the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company's management will engage in fireside chats during these events, with webcasts and replays accessible through the investor section of ORIC's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.82%
Tags
-
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) has announced a private placement of approximately 12.5 million shares of its common stock to institutional and accredited healthcare specialist investors, at a price per share of $10.00. The financing is expected to raise approximately $125 million and is anticipated to fund the company's research and development activities into late 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.89%
Tags
-
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) announced promising Phase 1b monotherapy data for ORIC-944 in metastatic prostate cancer, demonstrating a potential best-in-class profile. The company also highlighted operational achievements for 2023, including the initiation of multiple dose expansion cohorts for ORIC-114 and expected cash and investment to fund operations until 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) announced that CEO Jacob M. Chacko, M.D. will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The company focuses on developing treatments for therapeutic resistance in oncology. A live webcast of the presentation will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
-
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC) granted 23,080 non-qualified stock options and 3,840 restricted stock units to new non-executive employees. The options have an exercise price equal to the closing price of ORIC’s common stock on the Grant Date. The grants are subject to vesting conditions and were approved by ORIC’s Compensation Committee as a material inducement to employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) announced its participation in investor conferences in November, including the Jefferies London Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference. The company will be hosting fireside chats and webcasts of the discussions and presentations will be available through the investor section of the company’s website at www.oricpharma.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. presented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC, demonstrating a potential best-in-class profile. Initial Phase 1b data for ORIC-533 in patients with multiple myeloma will be presented at the 65th ASH Annual Meeting. Cash and investments of $256.2 million are expected to fund the operating plan into late 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
-
Rhea-AI Summary
ORIC Pharmaceuticals has granted 14,800 non-qualified stock options and 2,480 restricted stock units to a new non-executive employee. The grants were made under the 2022 Inducement Equity Incentive Plan and are subject to vesting conditions. The stock options have an exercise price equal to the closing price of ORIC's common stock on the grant date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
ORIC Pharmaceuticals, Inc. announced a poster presentation on the initial Phase 1b clinical data for ORIC-533 in patients with relapsed/refractory multiple myeloma at the 65th American Society of Hematology Annual Meeting. ORIC-533 is a highly potent and selective inhibitor of CD73, currently being evaluated in an ongoing Phase 1b study. The study included heavily pretreated patients and showed good tolerability, with no dose limiting toxicities or serious adverse events. Preliminary evidence of enhanced CD8+ T-cell activation and single agent clinical activity was observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
Rhea-AI Summary
ORIC Pharmaceuticals announces initial data from the ORIC-114 Phase 1 trial for EGFR/HER2 exon 20 mutated NSCLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Oric Pharmaceuticals, Inc.
Nasdaq:ORIC
ORIC Rankings
ORIC Stock Data
629.05M
37.08M
9.53%
88.37%
12.08%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
SOUTH SAN FRANCISCO
About ORIC
oric pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. its lead product candidate is oric-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. the company's second product candidate is oric-533, an orally bioavailable small molecule inhibitor of cd73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. it is also developing multiple precision medicines targeting other cancer resistance mechanisms. the company was founded in 2014 and is headquartered in south san francisco, california.